Single dose open-label comparative pharmacokinetic study to assess the pharmacokinetic characteristics of Irbesartan and Atorvastatin between Irbesartan/Atorvastatin combination tablet and coadministration of Irbesartan and Atorvastatin tablets in healthy male subjects : Irbesartan 150mg and Atorvastatin 20mg.
Phase of Trial: Phase I
Latest Information Update: 31 May 2017
At a glance
- Drugs Atorvastatin/irbesartan (Primary) ; Atorvastatin; Irbesartan
- Indications Heart failure; Hypercholesterolaemia; Hypertension; Hypertriglyceridaemia; Low HDL cholesterol
- Focus Pharmacokinetics
- Acronyms HM-IBAT-301
- Sponsors Hanmi Pharmaceutical
- 02 Apr 2012 Actual patient number added 52 according to ClinicalTrials.gov.
- 02 Apr 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 02 Apr 2012 Status changed from recruiting to completed 1 Dec 2011 as reported by ClinicalTrials.gov.